ABBOTT PARK, Ill., Feb. 6, 2026 – Abbott today announced positive early results from the VERITAS Study that show clinically meaningful closure rates of the investigational Amulet 360™ Left Atrial Appendage (LAA) Occluder, a next-generation implant designed to reduce risk of stroke in patients with atrial fibrillation (AFib) not caused by a heart valve issue (non-valvular). The results were presented in a late-breaking session at the AF Symposium in Boston on Feb. 6, 2026, and simultaneously published in JACC: Clinical Electrophysiology.
Results from the VERITAS Study show 93.9% of non-valvular AFib patients implanted with the Amulet 360 achieved complete closure of the LAA by 45 days, with no leaks greater than 3 mm.1 The LAA is a small, structurally complex pouch attached to the upper left chamber (atrium) of the heart, which is the most common place for blood clots to form and can potentially lead to stroke for people with this condition. The Amulet 360 device is a minimally invasive treatment option that can adapt to the unique shape of a patient’s LAA to immediately close it, potentially eliminating the need for blood-thinning medication when clinically appropriate. The next-generation Amulet 360 is built upon Abbott’s Amplatzer™ Amulet™ LAA Occluder, which has been in use in the U.S. since 2021 and in Europe since 2013. Amulet 360 includes design updates intended to enhance how the implant conforms to a patient’s heart.
Robust 45-day data for Abbott’s Amulet 360 LAA Occluder
The VERITAS Study included 400 patients at 34 sites across the U.S., Canada, and Europe. Key findings confirm the trial met its early benchmarks for safety and effectiveness with no complications such as additional surgery, strokes, or blood clots through seven days with a favorable closure rate at 45 days. 1 Results also show: 1
"Abbott is committed to developing minimally invasive approaches that help doctors address AFib and prevent strokes, ensuring optimal safety and benefits for patients," said Christopher Piorkowski, M.D., chief medical officer of Abbott's electrophysiology business. "With the next-generation Amulet 360, we are building upon the advancements we made with the introduction of our Amplatzer Amulet LAA Occluder, which was the first device in the industry to both close the LAA and create a seal over it, allowing people to forgo blood-thinning medication."
Follow up for the VERITAS Study is anticipated to conclude in 2027.
For U.S. important safety information about the current generation Amplatzer Amulet LAA Occluder go to: https://abbo.tt/AmuletISI.
Amulet 360™ Left Atrial Appendage Occluder is approved for investigational use only in the U.S.
About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 115,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.
1 Nair D. Early outcomes with a next-generation dual-seal device for left atrial appendage closure: Results from the VERITAS Amulet 360 Pivotal Study [Late Breaking Presentation]. Presented at: AF Symposium; February 6, 2026; Boston, MA, USA.
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
BACK TO PRESS RELEASES
